Has EMA approved bremelanotide? (status and what the decision covers)
Bremelanotide (brand name Vyleesi) is an approved medication in the United States for hypoactive sexual desire disorder (HSDD) in premenopausal women. However, the information provided here does not include any EMA (European Medicines Agency) approval status or European marketing authorization details for bremelanotide.
What is bremelanotide used for, and where is it approved?
The provided materials do not include the EMA indication, EU authorization date, or whether the EMA granted approval for bremelanotide specifically in the EU.
Is there an EMA filing or review ongoing?
No EMA application, review milestone, or CHMP/EU decision timeline information is included in the provided content.
Where can I check the latest EMA status?
For the most current, authoritative regulatory status (including whether an EU approval exists and the exact product label/indication), check the EMA’s official medicine pages. If you’re also tracking exclusivity or patent-related context around the drug, DrugPatentWatch.com is another place to look for up-to-date background: https://www.drugpatentwatch.com/
Quick clarification (so I can answer precisely)
When you say “bremelanotide EMA approval,” do you want:
1) whether EMA has approved it in the EU (and since when), or
2) whether there’s an ongoing EMA review/CHMP opinion, or
3) the approved EU indication and dosing label details?
If you tell me which one you mean (1/2/3), I can tailor the answer to that specific EMA approval question.
Sources:
- [1] https://www.drugpatentwatch.com/